Peter Ferenci

Summary

Affiliation: University of Vienna
Country: Austria

Publications

  1. ncbi Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies
    Peter Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    J Antimicrob Chemother 53:15-8. 2004
  2. ncbi Treatment of chronic viral hepatitis
    Peter Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, Medical University of Vienna, Wahringer Gurtel 18 20, Wien A 1090, Austria
    Best Pract Res Clin Gastroenterol 18:113-20. 2004
  3. pmc How to identify the genetic basis of gastrointestinal and liver diseases?
    P Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna Allgemeines Krankenhaus, Austria
    Gut 52:ii6-9. 2003
  4. ncbi Combination of interferon induction therapy and ribavirin in chronic hepatitis C
    P Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Austria
    Hepatology 34:1006-11. 2001
  5. ncbi Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998
    Peter Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Hepatology 35:716-21. 2002
  6. ncbi Hepatic transport systems
    Peter Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Austria
    J Gastroenterol Hepatol 17:S105-12. 2002
  7. ncbi Predictors of response to therapy for chronic hepatitis C
    Peter Ferenci
    Professor of Medicine, Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Vienna, Austria
    Semin Liver Dis 24:25-31. 2004
  8. ncbi Review article: diagnosis and current therapy of Wilson's disease
    P Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Austria
    Aliment Pharmacol Ther 19:157-65. 2004
  9. ncbi Weight-based dosing of pegylated interferon-alpha in chronic hepatitis C: just a marketing 'gag'?
    P Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Dig Liver Dis 35:601-6. 2003
  10. ncbi Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomized trial. Austrian Hepatitis Study Group
    P Ferenci
    Department of Internal Medicine IV, University of Vienna, Austria
    Eur J Gastroenterol Hepatol 13:699-705. 2001

Detail Information

Publications116 found, 100 shown here

  1. ncbi Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies
    Peter Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    J Antimicrob Chemother 53:15-8. 2004
    ..Patients who become HCV-RNA negative after 4 weeks have the best chance of achieving an SVR. The rapidity of viral elimination may be a useful guide to tailoring the length of treatment in patients with an EVR...
  2. ncbi Treatment of chronic viral hepatitis
    Peter Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, Medical University of Vienna, Wahringer Gurtel 18 20, Wien A 1090, Austria
    Best Pract Res Clin Gastroenterol 18:113-20. 2004
    ..No adefovir-associated resistance mutations of viral DNA were detected. Ongoing studies investigate combination therapy with lamivudine or IFN...
  3. pmc How to identify the genetic basis of gastrointestinal and liver diseases?
    P Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna Allgemeines Krankenhaus, Austria
    Gut 52:ii6-9. 2003
    ..To date, the most significant impact of genetics has been to increase our understanding of disease aetiology and pathogenesis and to reliably identify siblings of affected patients with the risk to develop symptomatic disease...
  4. ncbi Combination of interferon induction therapy and ribavirin in chronic hepatitis C
    P Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Austria
    Hepatology 34:1006-11. 2001
    ..3%, B: 75.9%, C: 56.3%; P >.1). These data indicate that high-dose interferon induction therapy may improve the outcome of interferon/ribavirin combination therapy in genotype 1 patients...
  5. ncbi Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998
    Peter Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Hepatology 35:716-21. 2002
    ..Finally, the need for a careful evaluation of the newer neuroimaging modalities for the diagnosis of hepatic encephalopathy was stressed...
  6. ncbi Hepatic transport systems
    Peter Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Austria
    J Gastroenterol Hepatol 17:S105-12. 2002
    ..Beyond these well defined diseases, functional impairments of transport proteins may predispose to non-genetic diseases ranging from intrahepatic cholestasis of pregnancy to neurodegenerative disorders including Alzheimer's disease...
  7. ncbi Predictors of response to therapy for chronic hepatitis C
    Peter Ferenci
    Professor of Medicine, Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Vienna, Austria
    Semin Liver Dis 24:25-31. 2004
    ..This article reviews the various patient and viral factors that help predict response to various interferon-based therapies, ranging from interferon alone to the new pegylated interferons...
  8. ncbi Review article: diagnosis and current therapy of Wilson's disease
    P Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Austria
    Aliment Pharmacol Ther 19:157-65. 2004
    ..Liver transplantation is reserved for severe or treatment-resistant cases with advanced liver disease, whilst experience with refractory neuropsychiatric disease is limited...
  9. ncbi Weight-based dosing of pegylated interferon-alpha in chronic hepatitis C: just a marketing 'gag'?
    P Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Dig Liver Dis 35:601-6. 2003
    ..Whether weight-based dosing of 12 kD linear PEG-IFNalpha2b provides any benefit over a flat dose of the drug remains to be studied...
  10. ncbi Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomized trial. Austrian Hepatitis Study Group
    P Ferenci
    Department of Internal Medicine IV, University of Vienna, Austria
    Eur J Gastroenterol Hepatol 13:699-705. 2001
    ..To investigate the efficacy of high-dose interferon alpha (IFN-alpha) with or without ribavirin in interferon (IFN) non-responders...
  11. ncbi [Therapy of chronic hepatitis C]
    P Ferenci
    Klinische Abteilung für Gastroenterologie und Hepatologie, Universitatsklinik fur Innere Medizin IV, Wahringer Gurtel 18 20, A 1090 Wien
    Wien Med Wochenschr 150:481-5. 2000
    ..Further improvements can be expected from high-dose induction therapy and from long-acting pegylated interferons. Nonresponders may benefit from antifibrotic agents, like long-term interferon therapy, IL-10 or silymarin...
  12. ncbi [The importance of Helicobacter--beyond the stomach too]
    P Ferenci
    Klinischen Abteilung für Gastroenterologie und Hepatologie, Universitatsklinik fur Innere Medizin IV, Wien
    Acta Med Austriaca 27:109-11. 2000
    ..Other strains (H. bilis, H. hepaticus, H. rappani, H. pullorum) may cause chronic hepatobiliary diseases or diarrhea. The possible role of such strains in carcinogenesis is very interesting and should be further explored...
  13. doi Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response
    Peter Ferenci
    Department of Internal Medicine III, Medical University, Vienna, Austria
    Gastroenterology 135:451-8. 2008
    ....
  14. doi Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy
    Peter Ferenci
    Internal Medicine 3, Department of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Gastroenterology 135:1561-7. 2008
    ..Oral Silibinin (SIL) is widely used for treatment of hepatitis C, but its efficacy is unclear. Substantially higher doses can be administered intravenously (IV)...
  15. doi Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection
    Sandra Beinhardt
    Internal Medicine III, Department of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Gastroenterology 142:78-85.e2. 2012
    ..We associated IL28B SNPs rs12979860 and rs8099917, along with serum levels of IP-10, with outcomes of patients with acute hepatitis C (AHC)...
  16. doi Intravenous silibinin as 'rescue treatment' for on-treatment non-responders to pegylated interferon/ribavirin combination therapy
    Karoline Rutter
    Department of Internal Medicine 3, Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Antivir Ther 16:1327-33. 2011
    ..In this proof-of-concept study, ivSIL was tested in on-treatment non-responders to full-dose of pegylated interferon-α2a/ribavirin (standard of care [SOC])...
  17. ncbi Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection
    Peter Ferenci
    Department of Internal Medicine IV, Medical University, Vienna, Austria
    J Hepatol 44:275-82. 2006
    ..Using a novel design, amantadine was studied in naïve genotype 1 patients treated in combination with peginterferon alfa-2a (40KD)/ribavirin...
  18. doi Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response
    Peter Ferenci
    Department of Internal Medicine III, Medical University, Vienna, Austria
    Gastroenterology 138:503-12, 512.e1. 2010
    ....
  19. ncbi CD4+ T cell responses in patients with chronic hepatitis C undergoing peginterferon/ribavirin therapy correlate with faster, but not sustained, viral clearance
    Judith H Aberle
    Institute of Virology, Medical University of Vienna, Vienna, 1095, Austria
    J Infect Dis 195:1315-9. 2007
    ..The detectability of NS3-4--directed Th1 responses was associated with faster viremia clearance, was short-lived, and did not seem to be associated with the final treatment outcome...
  20. ncbi Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy
    Petra Steindl-Munda
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Austria
    Liver Int 23:269-75. 2003
    ..This prospective, randomized, controlled study tested whether non-responders or relapsers to interferon monotherapy also benefit from induction therapy...
  21. ncbi Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection
    Wolfgang Jessner
    Department of Internal Medicine III, Gastroenterology and Hepatology, Vienna Medical University, Vienna, Austria
    Antivir Ther 13:581-9. 2008
    ..Our aim was to investigate this approach in genotype 4 patients...
  22. doi Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin
    Thomas Matthias Scherzer
    Department of Internal Medicine III, Medical University, Vienna, Austria
    Hepatology 54:1518-26. 2011
    ..9% and 18.8%; P < 0.025, respectively) and in those with low (<400,000 IU/mL: 37.5% versus 18.8%) and high (≥ 400,000 IU/mL: 45.0% versus 18.8%) baseline viral loads...
  23. doi A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis
    Monika Schmid
    Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Liver Int 30:574-82. 2010
    ..Several treatments have been introduced but only L-ornithine-L-aspartate (LOLA) shows proven efficacy. This double-blind, randomized, placebo-controlled trial evaluated the effect of LOLA on postural control in cirrhotics...
  24. doi A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3
    Peter Ferenci
    Department of Internal Medicine III, Medical University, Vienna, Austria
    Hepatology 47:1816-23. 2008
    ..4%-83.7%) in group B. Relapse rates in the 2 treatment groups were similar (17% in group A and 20% in group B). The incidence of adverse events, laboratory abnormalities, and dose reductions was similar in the 2 treatment groups...
  25. doi Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection
    Thomas Reiberger
    Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Clin Gastroenterol Hepatol 9:602-8.e1. 2011
    ..There are limited data on the efficacy and safety of antiviral therapy in patients with hepatitis C virus (HCV)-related cirrhosis, particularly on the impact of portal hypertension...
  26. ncbi Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin
    Elisabeth Formann
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Austria
    Am J Gastroenterol 99:873-7. 2004
    ..2 g ribavirin/d (COPEGUS, Roche, Nutley, USA) in de novo patients infected with HCV genotype 1. Sudden hearing loss and tinnitus developed on day 1 and after 4, 23, 25, 36, and 40 wk of treatment, respectively...
  27. ncbi Erythropoietin treatment is associated with more severe thrombocytopenia in patients with chronic hepatitis C undergoing antiviral therapy
    Monika Homoncik
    Department of Internal Medicine IV, Division of Gastroenterology, Medical University Vienna, Vienna, Austria
    Am J Gastroenterol 101:2275-82. 2006
    ..Further, we hypothesize that EPO increases platelet reactivity and protease activated receptor 1 (PAR-1) expression during combination antiviral therapy...
  28. doi Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C
    Albert Friedrich Stättermayer
    Division for Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    J Hepatol 57:492-8. 2012
    ..The aim of our study was to evaluate the role of these polymorphisms on insulin resistance (IR) in treatment-naïve patients with chronic hepatitis C...
  29. ncbi TGF-beta1 codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary hemochromatosis
    Christoph H Osterreicher
    Department of Internal Medicine IV, Medical University of Vienna, Austria
    Cytokine 31:142-8. 2005
    ..8 (95% CI 1.4-5.7, p = 0.004). In conclusion, C282Y homozygotes carrying TGF-beta1 genotypes Arg/Pro and Pro/Pro are more likely to develop cirrhosis than those with genotype Arg/Arg...
  30. ncbi Standard interferon-alpha in combination with ribavirin for hepatitis C patients with advanced liver disease and thrombocytopenia
    Harald Hofer
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Wien Klin Wochenschr 118:595-600. 2006
    ..We evaluated the safety, efficacy and tolerability of standard interferon-alpha in an accelerating dose regimen in combination with ribavirin in patients with HCV-induced liver cirrhosis and thrombocytopenia...
  31. ncbi Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a
    Harald Hofer
    Department of Internal Medicine IV, University of Vienna, Austria
    Am J Gastroenterol 97:2880-5. 2002
    ..Furthermore, the effect of hepatitis C virus (HCV) eradication by antiviral therapy on serum cholesterol levels was studied...
  32. doi Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin
    Thomas Matthias Scherzer
    Medical University of Vienna, Internal Medicine III, Department of Gastroenterology and Hepatology, Austria
    J Hepatol 54:866-71. 2011
    ..This study analyzes the impact of these IL28B polymorphisms on early treatment response (weeks 2 and 4) and SVR in HCV genotype 3 patients...
  33. ncbi Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C
    Harald Hofer
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, Medical University of Vienna, Waehringerguertel 18 20, A 1090 Vienna, Austria
    J Hepatol 40:1018-22. 2004
    ..In this study the role of hepatic iron concentration (HIC) and serum iron parameters was assessed to determine response to standard and pegylated interferon (IFN)/ribavirin combination therapy in patients with CHC...
  34. ncbi Association of myeloperoxidase promotor polymorphism with cirrhosis in patients with hereditary hemochromatosis
    Christoph H Osterreicher
    Department of Internal Medicine IV, Gastroenterology and Hepatology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Wien, Austria
    J Hepatol 42:914-9. 2005
    ..This study assessed the impact of polymorphisms of the MPO (-463G/A) and the HO-1 promotors of Vienna (GT)n on the evolution of cirrhosis in patients with HHC...
  35. doi Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C
    Albert Friedrich Stättermayer
    Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Clin Gastroenterol Hepatol 9:344-350.e2. 2011
    ..We investigated the roles of polymorphisms rs12979860 and rs8099917 on the early virologic response of treatment-naïve patients...
  36. doi Differentiation of nonalcoholic from alcoholic steatohepatitis: are routine laboratory markers useful?
    Lili Kazemi-Shirazi
    Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Wien Klin Wochenschr 120:25-30. 2008
    ..Specific markers for differentiation of nonalcoholic (NASH) from alcoholic steatohepatitis (ASH) are lacking. We investigated the role of routine laboratory parameters in distinguishing NASH from ASH...
  37. ncbi Diagnostic value of quantitative hepatic copper determination in patients with Wilson's Disease
    Peter Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, Medical University of Vienna, Austria
    Clin Gastroenterol Hepatol 3:811-8. 2005
    ..A 5-fold increase of hepatic copper concentration is considered as the best available test for diagnosis of hepatic Wilson's disease (WD). However, the sensitivity and specificity of this test have never been fully investigated...
  38. ncbi Antiviral therapy decreases GpIIb/IIIa activation of platelets in patients with chronic hepatitis C
    Wolfgang Sieghart
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, Medical University Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Thromb Haemost 95:260-6. 2006
    ..This does not result in an alteration of global platelet function as assessed by the PFA-100, because elevated vWF-Antigen levels might compensate for the acquired defect...
  39. ncbi Tongue and skin hyperpigmentation during PEG-interferon-alpha/ribavirin therapy in dark-skinned non-Caucasian patients with chronic hepatitis C
    Calin Gurguta
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Am J Gastroenterol 101:197-8. 2006
    ....
  40. doi IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients
    Berit A Payer
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Eur J Clin Invest 42:599-606. 2012
    ..The predictive value of interferon-gamma inducible protein 10 (IP10) on treatment outcome has been described in HCV patients. Data on combining these predictors in HIV-HCV-coinfected patients are not available...
  41. doi Percutaneous ethanol instillation therapy for hepatocellular carcinoma - a randomized controlled trial
    Christian Muller
    Universitätsklinik für Innere Medizin III, Klinische Abteilung für Gastroenterologie und Hepatologie, Medical University of Vienna, Austria
    Wien Klin Wochenschr 120:608-18. 2008
    ..The aim of the study was to compare the clinical outcome of additional percutaneous ethanol instillation (PEI) against no further treatment in patients with hepatocellular carcinoma receiving hormonal treatment with long-acting octreotide...
  42. doi Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus
    Sandra Beinhardt
    Internal Medicine III, Department of Gastroenterology and Hepatology, Medical University of Vienna, Austria
    Clin Infect Dis 56:118-22. 2013
    ..Based on viral kinetics, an even earlier prediction after 2 weeks of treatment with direct acting antivirals appears feasible...
  43. doi Treatment of chronic hepatitis C genotype 1 patients at an academic center in Europe involved in prospective, controlled trials: is there a selection bias?
    Sandra Beinhardt
    Internal Medicine III, Department of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Hepatology 55:30-8. 2012
    ..If analyzed according to the IL28B polymorphism, TPP SVR rates did not reach statistically significant differences among study and SOC patients...
  44. ncbi Late-onset Wilson's disease
    Peter Ferenci
    Department of Internal Medicine III, Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Gastroenterology 132:1294-8. 2007
    ..The clinical symptoms and age at onset of Wilson's disease (WD) are highly variable. This study investigated patients who became symptomatic at >40 years of age...
  45. doi Seminal fluid ribavirin level and functional semen parameters in patients with chronic hepatitis C on antiviral combination therapy
    Harald Hofer
    Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Waehringerguertel 18 20, Vienna, Austria
    J Hepatol 52:812-6. 2010
    ..The aim of this study was to evaluate seminal parameters and ribavirin and HCV-RNA concentrations in seminal fluid and serum prior to and during antiviral treatment...
  46. doi Hepatitis: Treatment of chronic hepatitis C-how much interferon is enough?
    Peter Ferenci
    Medical University of Vienna, Internal Medicine III, Department of Gastroenterology and Hepatology, Waehringer Guertel 18 20, A1090 Vienna, Austria
    Nat Rev Gastroenterol Hepatol 7:191-3. 2010
    ..High-dose PEG-IFN induction therapy did not enhance early or sustained virologic response rates compared with standard of care therapy...
  47. ncbi Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load
    Harald Hofer
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Austria
    Hepatology 37:60-4. 2003
    ..IFN therapy appears only needed in patients who fail to clear the virus within 35 days after onset of symptoms. By this approach, IFN therapy was not necessary in two thirds of patients with acute hepatitis C...
  48. ncbi Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
    Peter Ferenci
    Medical University of Vienna, Vienna, Austria
    J Hepatol 43:425-33. 2005
    ..Prediction of sustained virological response (SVR) during treatment would allow clinicians to identify patients most likely to benefit from therapy...
  49. ncbi Mutations of the HFE gene in patients with hepatocellular carcinoma
    Edmund Cauza
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Austria
    Am J Gastroenterol 98:442-7. 2003
    ..Patients with genetic hemochromatosis may be at risk for HCC, but limited information is available on the relationship of HCC and heterozygosity for the HFE gene mutations...
  50. ncbi Prospective study of viral clearance and CD4(+) T-cell response in acute hepatitis C primary infection and reinfection
    Judith H Aberle
    Institute of Virology, Medical University of Vienna, Austria
    J Clin Virol 36:24-31. 2006
    ..The outcome of acute hepatitis C is determined by early host-virus interactions, particularly involving the antiviral T-cell response...
  51. doi Identification of a novel Wilson disease gene mutation frequent in Upper Austria: a genetic and clinical study
    Harald Hofer
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    J Hum Genet 57:564-7. 2012
    ..None of the 100 healthy controls carried the mutation. We describe a novel mutation in the ATP7B gene, occurring in patients originated from a distinct geographical area in Austria associated with a variable course of the disease...
  52. doi Severity of organ failure is an independent predictor of intracranial hypertension in acute liver failure
    Reinhard Kitzberger
    Department of Gastroenterology, Hepatology and Medical Intensive Care Medicine, Medical University Hospital Vienna, Vienna, Austria
    Clin Gastroenterol Hepatol 7:1000-6. 2009
    ..We investigated whether the severity of organ failure was associated with intracranial hypertension and evaluated the correlation between NH(3) and pNH(3) and grade of hepatic encephalopathy...
  53. ncbi Increased C282Y heterozygosity in gestational diabetes
    Edmund Cauza
    Department of Internal Medicine V, Wilhelminenspital, Vienna, Austria
    Fetal Diagn Ther 20:349-54. 2005
    ....
  54. ncbi Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy
    E Formann
    Department of Internal Medicine IV, Gastroenterology and Hepatology, Medical University of Vienna, Austria
    Aliment Pharmacol Ther 23:507-11. 2006
    ..Little is known about long-term durability of HCV-RNA negativity in patient treated with pegylated interferon...
  55. doi Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection
    Peter Ferenci
    Department of Internal Medicine III, Medical University, Vienna, Austria
    Antivir Ther 16:1187-201. 2011
    ..Here, we review some of the complexities uncovered and controversies highlighted by the introduction of HCV protease inhibitors...
  56. ncbi Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia
    Simon Panzer
    Clinic for Blood Group Serology, Medical University Vienna, Vienna, Austria
    Eur J Haematol 77:513-7. 2006
    ....
  57. ncbi Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C
    T M Scherzer
    Internal Medicine III, Department of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Aliment Pharmacol Ther 28:742-8. 2008
    ..Efficacy and safety of antiviral combination therapy in patients with Crohn's disease (CD) and chronic hepatitis C (CHC) is presently not established and consequently CHC is rarely treated in CD patients...
  58. doi Peginterferon and ribavirin in HCV: improvement of sustained viral response
    P Ferenci
    Univ Klinik für Innere Medizin III, Medical University of Vienna, AKH, Wien, Austria
    Best Pract Res Clin Gastroenterol 22:1109-22. 2008
    ..Treatment duration may be shortened in patients with undetectable HCV-RNA after 4 weeks of therapy, on the other hand slow virologic responders may benefit from prolonged treatment...
  59. doi Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co-infection
    T Reiberger
    Department of Gastroenterology and Hepatology, University of Vienna, Vienna, Austria
    Eur J Clin Invest 38:421-9. 2008
    ..Differences in early viral kinetics have not been compared in these patients...
  60. pmc Shortening of treatment duration in patients with chronic hepatitis C genotype 2 and 3 - impact of ribavirin dose - a randomized multicentre trial
    Andreas Maieron
    Gastroenterology and Hepatology, Elisabethinen Hospital, Fadingerstrasse 1, Linz, 4020, Austria
    BMC Res Notes 4:220. 2011
    ..abstract:..
  61. ncbi Lack of evidence for involvement of fetal microchimerism in pathogenesis of primary biliary cirrhosis
    Maximilian Schoniger-Hekele
    Universitatsklinik fur Innere Medizin IV, Klinische Abteilung Gastroenterologie und Hepatologie, University of Vienna, Austria
    Dig Dis Sci 47:1909-14. 2002
    ..Our data suggest that microchimerism does not play a significant role in the development of PBC...
  62. doi Response guided therapy in patients with chronic hepatitis C - yesterday, today and tomorrow
    Peter Ferenci
    Internal Medicine 3, Gastroenterology and Hepatology, Medical University of Vienna, Austria
    Best Pract Res Clin Gastroenterol 26:463-9. 2012
    ..Patients with eRVR can be cured by an abbreviated treatment regime. Further modification and unification of response criteria are needed for the currently evaluated interferon-free treatment regimes...
  63. ncbi Pathophysiology and clinical features of Wilson disease
    Peter Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Metab Brain Dis 19:229-39. 2004
    ..Initial treatment for symptomatic patients should include a chelating agent (penicillamine or trientine). Treatment of presymptomatic patients or maintenance therapy can also be accomplished with zinc...
  64. ncbi Hepatitis C viral dynamics: basic concept and clinical significance
    Wolfgang Jessner
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University Hospital, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    J Clin Virol 25:S31-9. 2002
    ..Furthermore, limitations of currently available quantitative assays will be discussed...
  65. ncbi Regional distribution of mutations of the ATP7B gene in patients with Wilson disease: impact on genetic testing
    Peter Ferenci
    Department of Internal Medicine IV, University of Vienna, Wahringer Gurtel 18 20, 1090, Vienna, Austria
    Hum Genet 120:151-9. 2006
    ..Knowledge of the differences in the worldwide distribution of particular mutations will help to design shortcuts for genetic diagnosis of WD...
  66. pmc Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens
    M Schmid
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, University of Vienna, Währingergürtel 18 20, A 1090 Vienna, Austria
    Gut 54:1014-20. 2005
    ..Treatment of chronic hepatitis C with interferon (IFN)-alpha and ribavirin has haematotoxic effects. We evaluated the effects of four different IFN/IFN-ribavirin treatment regimens on haematopoiesis...
  67. ncbi Short- and long-term effects of therapy with interferon-alpha and pegylated interferon-alpha/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C
    M Homoncik
    Division of Gastroenterology and Hepatology, Department of Internal Medicine IV, Medical University, Vienna, Austria
    Aliment Pharmacol Ther 21:49-55. 2005
    ..A pegylated interferon-alpha-induced decrease in platelet counts may become a limiting factor for continuation of therapy...
  68. ncbi Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection
    W Jessner
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Vienna, Austria
    J Viral Hepat 10:37-42. 2003
    ..Antiviral response to PEG-IFN-alpha-2a is different to that on standard IFN. In spite of a lower initial response PEG-IFN-alpha-2a/ribavirin combination therapy may overcome predicted IFN unresponsiveness...
  69. ncbi Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1
    E Formann
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Austria
    J Viral Hepat 10:271-6. 2003
    ..001). To achieve continuous drug exposure and to improve initial viral clearance, peginterferon-alpha-2b has to be given at least two times weekly...
  70. ncbi Prospective pilot study of recombinant granulocyte-macrophage colony-stimulating factor and interferon-gamma in patients with inoperable hepatocellular carcinoma
    Walter Reinisch
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    J Immunother 25:489-99. 2002
    ..Immunotherapeutic approaches hold promise to prolong survival in selected patients with advanced HCC who respond by enhanced tumor immunogenicity...
  71. ncbi Morbidity and mortality in paid Austrian plasma donors infected with hepatitis C at plasma donation in the 1970s
    Peter Ferenci
    Department of Internal Medicine IV, Medical University of Vienna, Austria
    J Hepatol 47:31-6. 2007
    ..Data collected by a Foundation to help the victims enabled us to study the natural history of chronic hepatitis C in this cohort...
  72. doi Non-invasive assessment of hepatic fat accumulation in chronic hepatitis C by 1H magnetic resonance spectroscopy
    Martin Krssak
    Department of Internal Medicine III, Division of Endocrinology and Metabolism, Medical University of Vienna, Austria
    Eur J Radiol 74:e60-6. 2010
    ..Liver biopsy is the standard method for diagnosis of hepatic steatosis, but is invasive and carries some risk of morbidity...
  73. doi [4. Austrian consensus-statement for diagnosis and therapy of hepatitis B 2009]
    Markus Peck-Radosavljevic
    Osterreichische Gesellschaft für Gastroenterologie und Hepatologie, Arbeitsgruppe Leber, Wien, Austria
    Wien Klin Wochenschr 122:280-302. 2010
    ..Overall this consensus statement accounts for the major advances in the management of hepatitis B and significantly changes clinical management of patients with hepatitis B in Austria...
  74. ncbi Wilson's Disease
    Peter Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Clin Gastroenterol Hepatol 3:726-33. 2005
    ..Alternatively, haplotype analysis can be used to address diagnostic dilemmas in differentiating heterozygote gene carriers and affected asymptomatic siblings...
  75. ncbi Pegylated interferon plus ribavirin for chronic hepatitis C: the role of combination therapy today, tomorrow and in the future
    P Ferenci
    Department of Internal Medicine IV, Medical University of Vienna, Vienna, Austria
    Minerva Gastroenterol Dietol 52:157-74. 2006
    ..Although several promising oral agents have been identified and are currently in clinical development, it seems likely that pegylated interferon will remain the backbone of therapy for years to come...
  76. ncbi Peginterferon alfa-2a (40KD) (Pegasys) for the treatment of patients with chronic hepatitis C
    P Ferenci
    University Clinic of Internal Medicine IV, Vienna, Austria
    Int J Clin Pract 57:610-5. 2003
    ..Peginterferon alfa-2a (40KD) is widely approved for use in patients with chronic hepatitis C...
  77. ncbi Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha
    Markus Peck-Radosavljevic
    Department of Gastroenterology and Hepatology, University of Vienna, Vienna, Austria
    Gastroenterology 123:141-51. 2002
    ..Treatment of chronic hepatitis C with interferon (IFN)-alpha often has hematotoxic effects. We evaluated the effects of acute vs. chronic and standard vs. pegylated IFN-alpha on hematopoiesis...
  78. ncbi Liver pathology in compound heterozygous patients for hemochromatosis mutations
    Maximilian Schoniger-Hekele
    Universitatsklinik fur Innere Medizin IV, Klinische Abteilung Gastroenterologie und Hepatologie, University of Vienna, Austria
    Liver 22:295-301. 2002
    ..While hepatic pathology of homozygous carriers of the C282Y mutation of the HFE haemochromatosis gene is well defined, the impact of the C282Y/H63D compound heterozygous carrier state is unknown...
  79. ncbi Subclinical impairment of brain function in chronic hepatitis C infection
    Ludwig Kramer
    Department of Medicine IV, University Hospital Vienna, Wahringer Gurtel 18 20, Vienna, Austria
    J Hepatol 37:349-54. 2002
    ..This study tested the hypothesis of a subclinical cognitive dysfunction in HCV-infected patients...
  80. ncbi Paraneoplastic pemphigus in association with hepatocellular carcinoma
    Gabriele Hinterhuber
    Department of Dermatology, School of Medicine, University of Vienna, Austria
    J Am Acad Dermatol 49:538-40. 2003
    ..This patient met all diagnostic criteria for paraneoplastic pemphigus and is, to our knowledge, the first report of a case associated with hepatocellular carcinoma...
  81. doi Hepatocellular carcinoma in long-term sustained virological responders following antiviral combination therapy for chronic hepatitis C
    T M Scherzer
    Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    J Viral Hepat 15:659-65. 2008
    ..Long-term follow up of patients with SVR is mandatory and should include surveillance for hepatocellular carcinoma...
  82. ncbi Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C
    M Peck-Radosavljevic
    Department of Gastroenterology and Hepatology, University of Vienna, Vienna, Austria
    Hepatology 28:1424-9. 1998
    ..Recombinant human TPO could be of value in patients developing severe thrombocytopenia under IFN- therapy...
  83. ncbi Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial
    C Muller
    Universitatsklinik fur Innere Medizin IV, Klinische Abteilung Gastroenterologie und Hepatologie, Vienna, Austria
    Eur J Gastroenterol Hepatol 10:865-70. 1998
    ..Recently, the serotonin antagonist ondansetron has been reported to have a positive effect on cholestasis-associated pruritus...
  84. ncbi A novel variant of lysosomal acid lipase in cholesteryl ester storage disease associated with mild phenotype and improvement on lovastatin
    C Gasche
    Department of Gastroenterology and Hepatology, University of Vienna, Austria
    J Hepatol 27:744-50. 1997
    ..5% (p<0.05) and 41.7+/-5.1% to 33.4+/-4.4% (p<0.01). We conclude that in two siblings with a novel LAL variant and mild phenotype of CESD, lovastatin decreased both serum lipid concentrations and hepatocellular lysosomal content...
  85. ncbi Comparison of the Bayer VERSANT HCV RNA 3.0 and the Roche COBAS Amplicor HCV Monitor, Version 2.0, assays in HCV genotype 4 infection
    W Jessner
    Department of Internal Medicine IV, Gastroenterology and Hepatology, Vienna Medical University, Vienna, Austria
    J Viral Hepat 14:775-81. 2007
    ..The interpretation of viral kinetic data becomes difficult due to overestimation upon dilution of baseline values by HCM-2.0...
  86. ncbi Bi-allelic presence of the interleukin-10 receptor 1 G330R allele is associated with cirrhosis in chronic HCV-1 infection
    H Hofer
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, Medical University of Vienna, Austria
    Genes Immun 6:242-7. 2005
    ..Our work implies that IL-10R1 SNP4 is a recessively inherited risk factor for hepatic cirrhosis in HCV genotype-1 infection...
  87. ncbi Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipients
    J Kletzmayr
    Department of Medicine, University of Vienna, Vienna, Austria
    Transplantation 70:1404-7. 2000
    ..Chronic hepatitis B virus (HBV) infection increases morbidity and mortality in renal transplant recipients (RTR). Lamivudine has shown promising results in patients with chronic hepatitis B, but experience with its use in RTR is limited...
  88. ncbi Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production
    M Peck-Radosavljevic
    Department of Gastroenterology and Hepatology, University of Vienna, Austria
    Blood 95:795-801. 2000
    ..Decreased TPO production in the cirrhotic liver is an important etiologic factor for thrombocytopenia in liver disease that is rapidly reversed by transplantation...
  89. ncbi Partial pressure of ammonia versus ammonia in hepatic encephalopathy
    L Kramer
    University Hospital Vienna, Department of Medicine IV, Vienna, Austria
    Hepatology 31:30-4. 2000
    ..These findings support the ammonia hypothesis of HE and suggest that pNH(3) might be superior to total ammonia in the pathophysiological evaluation of HE...
  90. ncbi A controlled study of sorbent suspension dialysis in chronic liver disease and hepatic encephalopathy
    L Kramer
    Department of Medicine IV, University of Vienna Medical School, Austria
    Int J Artif Organs 24:434-42. 2001
    ..In conclusion, a six-hour treatment with sorbent suspension dialysis did not ameliorate the clinical stage of HE but improved neurophysiologic function in cirrhotic patients who had not responded to conventional medical treatment...
  91. ncbi Preoperative TNM-classification is a better prognostic indicator for recurrence of hepatocellular carcinoma after liver transplantation than albumin mRNA in peripheral blood. Liver Transplant Oncology Group
    M Peck-Radosavljevic
    Department of Gastroenterology and Hepatology, University of Vienna, Austria
    J Hepatol 28:497-503. 1998
    ....
  92. ncbi Development of insulin-dependent diabetes mellitus in a patient with chronic hepatitis C during therapy with interferon-alpha
    N Eibl
    Department of Internal Medicine 1, Rudolfstiftung Hospital, Vienna, Austria
    Eur J Gastroenterol Hepatol 13:295-8. 2001
    ..In patients found to be at increased risk of developing diabetes mellitus type 1, monitoring of titres of these antibodies during therapy could help to assess the individual risk-benefit ratio of IFN-alpha treatment...
  93. ncbi Prevalence and distribution of hepatitis C subtypes in patients with opioid dependence
    W Gombas
    Drug Addiction Out Patient Clinic, Department of General Psychiatry, University Hospital for Psychiatry, Vienna, Austria
    Eur Addict Res 6:198-204. 2000
    ....
  94. ncbi Wilson disease
    Reinhard Kitzberger
    Department of Internal Medicine IV, Gastroenterology and Hepatology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090, Vienna, Austria
    Metab Brain Dis 20:295-302. 2005
    ..Presence of liver disease, neurologic symptoms, and Kayser-Fleischer corneal rings are the hallmarks of the disease...
  95. ncbi HFE genotyping demonstrates a significant incidence of hemochromatosis in undifferentiated arthritis
    E Cauza
    Department of Internal Medicine V, Department of Rheumatology, Wilhelminenspital, Vienna, Austria
    Clin Exp Rheumatol 23:7-12. 2005
    ..In this study the two frequent mutations of the HLA-linked hemochromatosis gene (HFE) were investigated in a rheumatology clinic population...
  96. ncbi Dysfunction of the liver affects the sense of smell
    Andreas F P Temmel
    Department of Otorhinolaryngology, University of Vienna, AKH Wien, Vienna, Austria
    Wien Klin Wochenschr 117:26-30. 2005
    ....
  97. ncbi Transjugular intrahepatic portosystemic shunt in Vienna--a decade later
    Bernhard Angermayr
    Department of Internal Medicine IV, University of Vienna, Vienna, Austria
    Wien Klin Wochenschr 116:608-13. 2004
    ....
  98. pmc Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation
    H Hofer
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, Medical University of Vienna, Austria
    J Clin Pathol 59:246-9. 2006
    ..Centrilobular necrosis (CN), reminiscent of toxic or circulatory liver injury, has been reported in AIH. The aim of this study was to assess the frequency of CN in patients with AIH and its correlation with laboratory and clinical data...
  99. ncbi Relative impact of fatigue and subclinical cognitive brain dysfunction on health-related quality of life in chronic hepatitis C infection
    Ludwig Kramer
    Department of Medicine IV, Medical University Vienna, Austria
    AIDS 19:S85-92. 2005
    ..To assess the relative impact of fatigue and subclinical cognitive brain dysfunction on the impairment of health-related quality of life (HRQL) in hepatitis C virus (HCV) infection...
  100. ncbi The host or the virus? Impact of genetic factors on the outcome of hepatitis C virus infection
    Peter Ferenci
    Gastroenterology 131:954-6. 2006
  101. ncbi Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy
    Donald M Jensen
    Center for Liver Diseasees, University of Chicago Hospitals, 60637, USA
    Hepatology 43:954-60. 2006
    ..In conclusion, patients infected with HCV genotype 1 and treated with peginterferon alpha-2a/ribavirin sustained a RVR 24% of the time. This portends an 89% probability of a SVR after 24 weeks of treatment...